NCT05086835

Brief Summary

Even when treated with methadone or buprenorphine maintenance, many people with opioid use disorder (OUD) continue to experience craving. Among both users of heroin and users of prescription opioids, mounting evidence shows that craving predicts return to use and undermines existing treatments for OUD, thus, the development of new interventions to reduce craving is a priority for addressing the opioid crisis (NIH HEAL Initiative Research Plan, 2019). Deficits in executive functioning, particularly working memory, are a central mechanism that undermines the ability to inhibit craving. Laboratory studies in non-clinical samples show that engaging in working memory tasks before or during a craving induction increases the ability to resist craving. This suggests that people with OUD may benefit from engaging in working memory tasks at the specific moment when craving occurs. Although previous research shows that working memory "training" does not improve clinical outcomes in OUD, these studies have not delivered training at the moment that craving actually occurs in daily life. Thus, engaging in working memory tasks at the moment that craving occurs could presumably help individuals with OUD to manage this persistent symptom, but this has not been tested. Further, studies using Ecological Momentary Assessment (EMA) methods show that people with OUD can accurately track moment-to-moment fluctuations in craving in their daily lives, suggesting that it may be feasible to deliver interventions for craving in the moment when craving is reported. This study will test the efficacy of embedding a mobile cognitive intervention into an EMA design in people with OUD. Using the NIH Stage Model of Intervention Development, Stage 1A of this project will optimize a working memory intervention based on iterative feedback from a sample of people with OUD (n = 20), in preparation for a Stage 1B trial using a randomized design. In this trial, participants with OUDs (n = 60) will complete a two-week EMA study in which they complete smartphone-based assessments of craving five times daily. When craving is reported, a mobile application containing the working memory intervention will activate. Half of the participants will complete the intervention, while half will complete a control task. At the conclusion of the trial, participants will be granted unrestricted access to the intervention during a feasibility phase. Outcomes include change in momentary craving, change in working memory performance, and feasibility and acceptability, including use of the intervention during follow-up. Substance use will also be assessed. This project supports the applicant's goal of leveraging cognitive mechanisms to conduct treatment development research for OUD. The applicant will receive training in the etiology and treatment of OUD, craving, mobile intervention development and human-centered design of interventions, and analysis of intensive longitudinal data. With its emphasis on modifying cognitive processes at the moment of craving, using mobile devices in patients' daily lives, this project has the potential to reveal new pathways for addressing a significant predictor of relapse in OUD.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2021

Completed
13 days until next milestone

Study Start

First participant enrolled

October 14, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 21, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
3 months until next milestone

Results Posted

Study results publicly available

June 10, 2022

Completed
Last Updated

June 10, 2022

Status Verified

May 1, 2022

Enrollment Period

5 months

First QC Date

October 1, 2021

Results QC Date

April 7, 2022

Last Update Submit

May 13, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Modified Craving Scale

    A single-item craving measure adapted from the 3-Item Craving Scale (Weiss et al., 2003).

    Change from pre-task to immediately post-task

  • Dot Matrix Working Memory Task

    A computerized version of a visual-spatial working memory task.

    Change from baseline to post-trial (at 2 weeks)

Study Arms (2)

Working Memory App (Active Intervention)

EXPERIMENTAL

A visual-spatial app-based working memory intervention.

Other: Working Memory Task

Visual Search App (Control Condition)

ACTIVE COMPARATOR

An app-based visual search task to be used as a control condition.

Other: Visual Search Task

Interventions

A smartphone-based visual-spatial working memory task that will be optimized in the Stage 1A phase of this study.

Working Memory App (Active Intervention)

A smartphone-based visual search task that will be optimized in the Stage 1A phase of this study.

Visual Search App (Control Condition)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 or older
  • Currently receiving opioid use disorder treatment at McLean Hospital
  • Primary diagnosis of opioid use disorder
  • Currently prescribed medication treatment (agonist/partial agonist or antagonist) for opioid use disorder (\*Note: does not apply to Stage 1A participants).
  • Own a smartphone with a touchscreen and a current data plan

You may not qualify if:

  • Acute suicidal ideation
  • Acute psychosis
  • Diagnosis of a neurological disorder
  • History of stroke
  • Diagnosis of a brain disease affecting cognitive function (e.g., tumor)
  • Score of less than 26 on the Montreal Cognitive Assessment (MoCA)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

McLean Hospital

Belmont, Massachusetts, 02478, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Limitations and Caveats

This study was terminated prior to enrolling participants in either of the clinical trial study arms, so no outcome data were collected. Baseline data on the 10 participants who entered the Stage 1A study (designed to help inform the development of the clinical trial) are provided in the Baseline Characteristics section.

Results Point of Contact

Title
Dr. Roger Weiss
Organization
McLean Hospital

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Instructor in Psychology

Study Record Dates

First Submitted

October 1, 2021

First Posted

October 21, 2021

Study Start

October 14, 2021

Primary Completion

March 1, 2022

Study Completion

March 1, 2022

Last Updated

June 10, 2022

Results First Posted

June 10, 2022

Record last verified: 2022-05

Locations